EIF4EBP1 and cancer: Weaker p-4EBP1 positivity indicated longer 3-year and 5-year overall survival among patients with stage I–IV (P = 0.0005 and P = 0.001), stage I–II (P = 0.0002 and P = 0.002), stage II–IV (P = 0.01 and P = 0.003), and stage II–IV (P = 0.0008 and P = 0.003) cancers.